{"prompt": "['Protocol RS-001', 'Confidential', '9.1', 'CLINICAL ASSESSMENTS', '46', '9.2', 'CLINICAL LABORATORY MEASUREMENTS', '48', '9.3', 'PHARMACOKINETIC MEASUREMENTS', '49', '9.4', 'RESEARCH LABORATORY MEASUREMENTS', '49', '9.5', 'SPECIMENS FOR LONG-TERM BIOREPOSITORY STORAGE', '49', '10', 'EVALUATIONS BY VISIT', '49', '10.1', 'SCREENING ASSESSMENTS (DAY - 14 TO 0)', '49', '10.2', 'VISIT 1 - MAY ALSO BE SCREENING VISIT (DAY 0)', '50', '10.3', 'VISIT 2 - END OF BASELINE (DAY 30 ++5/-2 DAYS)', '50', '10.4', 'VISITS 3, 4, & 5: ABI-009 DOSES 1-3 (+/-2 DAYS)', '51', '10.5', 'VISIT 6: POST-DOSING ONE-WEEK ASSESSMENT (+/-2 DAYS)', '51', '10.6', 'FOLLOW-UP VISITS 7, 8, & 9: 30, 60, AND 90 DAYS POST-DOSING (+/-7 DAYS)', '52', '10.7', 'EARLY PERMANENT DISCONTINUATION OF STUDY DOSING', '52', '11', 'ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION', '53', '11.1', 'ADVERSE EVENTS', '53', '11.2', 'SERIOUS ADVERSE EXPERIENCES (SAE)', '54', '11.3', 'MEDICAL MONITORING', '54', '11.4', 'MONITORING SUSPECTED TOXICITIES FOR DISCONTINUED PARTICIPANTS', '54', '12', 'DISCONTINUATION AND REPLACEMENT OF PARTICIPANTS', '55', '12.1', 'EARLY PERMANENT DISCONTINUATION OF ABI-009 DOSING', '55', '12.2', 'SCREEN FAIL CRITERIA', '55', '12.3', 'EARLY WITHDRAWAL OF PARTICIPANTS FROM THE STUDY', '55', '12.4', 'REPLACEMENT OF PARTICIPANTS', '56', '13', 'PROTOCOL VIOLATIONS', '56', '14', 'DATA SAFETY MONITORING', '56', '15', 'STATISTICAL METHODS AND CONSIDERATIONS', '56', '15.1', 'GENERAL CONSIDERATIONS', '56', '15.2', 'DEMOGRAPHIC AND BASELINE CHARACTERISTICS', '57', '15.3', 'ANALYSIS OF PRIMARY ENDPOINT - SAFETY ENDPOINTS', '57', '15.4', 'ANALYSIS OF PRIMARY ENDPOINT - TOLERABILITY (STUDY DRUG DISCONTINUATION AND COMPLIANCE)', '58', '15.5', 'ANALYSIS OF SECONDARY ENDPOINTS', '58', '15.6', 'SAMPLE SIZE', '58', '16', 'DATA COLLECTION, RETENTION AND CLINICAL MONITORING', '58', '16.1', 'DATA COLLECTION INSTRUMENTS', '58', '16.2', 'AVAILABILITY AND RETENTION OF INVESTIGATIONAL RECORDS', '59', '16.3', 'MONITORING', '60', '16.4', 'PARTICIPANT CONFIDENTIALITY', '60', '17 ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS', '60', '17.1', 'PROTOCOL AMENDMENTS', '60', '17.2', 'INSTITUTIONAL REVIEW BOARD', '60', '17.3', 'INFORMED CONSENT FORM', '61', '17.4', 'PUBLICATIONS', '61', '17.5', 'INVESTIGATOR RESPONSIBILITIES', '62', '18 REFERENCES', '62', 'Version 2', 'Version Date: October 31, 2018', 'Page 4 of 72']['Protocol RS-001', 'Confidential', 'APPENDIX 1. SCHEDULE OF EVENTS', '71', 'LIST OF TABLES', 'Table 1: Predicted Rapamycin Blood Levels after ABI-009 IV Administration', '30', 'Table 2: Rapamycin Levels in Brain and Blood after ABI-009 IV Administration', '33', 'Table 3: ABI-009 Cohort Dosing Schedule', '37', 'Table 4: Hematological and non-hematological toxicities and ABI-009 dosing adjustments', '43', 'Table 5. Pneumonitis Management and ABI-009 Dosing', '46', 'Table 6. Weight Specific Guidelines for Therapeutic Use of Loperamide', '47', 'Table 7. AE Severity Grading', '55', 'LIST OF FIGURES', 'Figure 1: Tumor Volume and Animal Survival following Treatment with IV ABI-009 and', 'Oral mTOR Inhibitors', '30', 'Figure 2:', 'Distribution of Radioactivity in Tissues in Male Rats', '31', 'Version 2', 'Version Date: October 31, 2018', 'Page 5 of 72']\n\n###\n\n", "completion": "END"}